Teva Pharmaceutical Industries Ltd. (TEVA) said Monday that the U.S. Food and Drug Administration approved IGALMI (dexmedetomidine) sublingual film for at-home use. That makes it the first FDA-approved treatment adults can take at home for acute agitation associated with schizophrenia, schizoaffective disorder, or bipolar I or II disorder.
For the uninitiated: IGALMI is a prescription medicine placed under the tongue or between the lower lip and gum, designed to treat sudden (acute) agitation in adults with those conditions. Think of it as a fast-acting option that doesn't require a trip to a clinic.
Phase 3 Trial Confirms Consistent Tolerability
The 12-week Phase 3 SERENITY At-Home Safety and Tolerability Trial treated 1,160 agitation episodes across 102 patients with IGALMI. Patients maintained consistent tolerability with repeat dosing throughout the study period, and zero participants discontinued treatment due to tolerability concerns. That's a clean sheet on the dropout front.
The most frequent adverse events, occurring in at least 5% of patients and exceeding placebo rates, included somnolence, dry mouth, dizziness, and oral paresthesia or oral hypoesthesia. Not exactly a beach vacation, but manageable for a condition that needs rapid relief.
BioXcel Asset Deal And Regulatory Path
Teva acquired IGALMI in late October 2026 from BioXcel Therapeutics, Inc., securing worldwide rights to the investigational sublingual film previously known as BXCL501. The company paid $57.5 million upfront and agreed to provide up to $67.5 million in contingent payments. That's a relatively modest bet for a first-in-class at-home approval.
TEVA Price Action: Teva Pharmaceutical Indus shares were down 2.40% at $43.43 at the time of publication on Monday. The stock is approaching its 52-week high of $44.56, according to market data.